Home
About
Our History
Senior Management
Board Of Directors
Medical Advisory Board Members
Products
The VenoValve
®
CoreoGraft
®
– Bypass Graft
Contact
Careers
Investors
Overview
Investor Presentation
News / Events
Company Information
Financial Information
Stock Data
SEC Filings
Corporate Governance
Proxy Information
Home
About
Our History
Senior Management
Board Of Directors
Medical Advisory Board Members
Products
The VenoValve™
CoreoGraft™ – Bypass Graft
Contact
Careers
Investors
Overview
Investor Presentation
News / Events
Company Information
Financial Information
Stock Data
Analyst Coverage
SEC Filings
Corporate Governance
Proxy Information
Articles & Publications
Investors
Overview
Investor Presentation
News / Events
Recent News / Events
Press Releases
Articles & Publications
IR Calendar
Email Alerts
Company Info
Overview
Profile
Management Team
Contacts
FAQ
Financial Info
Overview
Balance Sheet
Income Statement
Cash Flow
Financial Results
Stock Data
Overview
Quote
Charts
Historical Data
Analyst Coverage
SEC Filings
Overview
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Proxy Information
Governance
Overview
Board of Directors
Board Committees
Governance Documents
News / Events
Recent News / Events
Press Releases
Articles & Publications
IR Calendar
Email Alerts
Hancock Jaffe Gears Up for Pivotal Trial to Treat Chronic Venous Insufficiency
Feb 15, 2021
Hancock Jaffe, maker of the VenoValve, completes US$41 million public offering
Feb 12, 2021
Hancock Jaffe completes $41M offering
Feb 12, 2021
Hancock Jaffe completes $41M offering
Feb 12, 2021
MedTech Insight: Hancock Jaffe Sells $41.4M In Stock To Fund Venous Therapies
Feb 11, 2021
Hancock Jaffe Completes $41 Million Public Offering
Feb 11, 2021
Hancock Jaffe Prepares for the VenoValve United States Pivotal Trial
Feb 11, 2021
Show
/
Refresh
/
Reset
/
Delete
Views until show:
5
Seconds until show:
5
By using this website, you consent to the use of cookies, as described in our
privacy policy
.
Accept
